NEW YORK (GenomeWeb) – Guardant Health announced today a multiyear agreement with AstraZeneca to develop blood-based companion diagnostic tests for drugs in the pharma firm's oncology portfolio.
Under the terms of the agreement, Guardant is developing and pursuing FDA approval for a companion test that will help identify non-small cell lung cancer patients likely to respond to Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR inhibitor.